Geng Zhixin, Wang Wen, Zhu Yuanyuan, Xu Yan, Chen Qiang, Zhang Lei, Yu Jing, Sun Xiang, Wang Zhiguo
Department of Laboratory Medicine, Jiangsu Province (Suqian) Hospital, Suqian, Jiangsu, China.
Department of Rheumatology and Immunology, Jiangsu Province (Suqian) Hospital, Suqian, Jiangsu, China.
Front Immunol. 2025 Aug 14;16:1630442. doi: 10.3389/fimmu.2025.1630442. eCollection 2025.
This study evaluated trends in population immunity against measles, rubella, mumps, and varicella in Suqian City (2005-2024) using serological surveys (2019-2024) and incidence data, incorporating participants with known/unknown vaccination statuses to explore immunity dynamics amid evolving policies, and inform public health planning.
Serum samples from 541 (2019) and 506 (2024) healthy participants were analyzed for virus-specific IgG antibodies using ELISA. Disease incidence data were obtained from China's National Notifiable Disease Reporting System. Statistical analyses compared seroprevalence, geometric mean concentrations (GMCs), and incidence trends before and after policy adjustments.
Optimized two-dose strategies significantly improved seropositivity rates for rubella (65.1% to 70.8%), mumps (77.6% to 85.8%), and varicella (76.9% to 79.5%), with corresponding GMC increases. Incidence declines were notable: varicella (183.3/100,000 to 59.3/100,000), rubella (2.8/100,000 to 0.04/100,000), and mumps (24.4/100,000 to <5.0/100,000). However, measles seropositivity declined from 85.9% to 79.3% (p<0.05). GMC analysis showed increases for rubella (31.5 to 42.2 IU/ml), mumps (277.8 to 350.6 IU/ml), and varicella (295.9 to 309.8 IU/ml), but a decrease for measles (577.9 to 499.2 mIU/ml, p<0.001). Preschool children (2-5 years) exhibited the highest immunity levels in 2024.
Population immunity against rubella, mumps, and varicella improved (2019-2024) with reduced incidence, while measles immunity declined, revealing vulnerabilities. Targeted strategies (e.g., catch-up campaigns for adolescents/adults, optimized infant vaccination) are needed to strengthen protection, considering interactions of policies, public health measures, and demographics.
本研究利用血清学调查(2019 - 2024年)和发病率数据,评估宿迁市(2005 - 2024年)人群对麻疹、风疹、腮腺炎和水痘的免疫趋势,纳入已知/未知疫苗接种状态的参与者,以探索政策演变过程中的免疫动态,并为公共卫生规划提供信息。
采用酶联免疫吸附测定法(ELISA)分析了541名(2019年)和506名(2024年)健康参与者的血清样本中的病毒特异性IgG抗体。疾病发病率数据来自中国国家法定传染病报告系统。统计分析比较了政策调整前后的血清阳性率、几何平均浓度(GMCs)和发病率趋势。
优化的两剂次策略显著提高了风疹(从65.1%提高到70.8%)、腮腺炎(从77.6%提高到85.8%)和水痘(从76.9%提高到79.5%)的血清阳性率,相应的GMCs也有所增加。发病率显著下降:水痘(从183.3/10万降至59.3/10万)、风疹(从2.8/10万降至0.04/10万)和腮腺炎(从24.4/10万降至<5.0/10万)。然而,麻疹血清阳性率从85.9%降至79.3%(p<0.05)。GMC分析显示风疹(从31.5升至42.2 IU/ml)、腮腺炎(从277.8升至350.6 IU/ml)和水痘(从295.9升至309.8 IU/ml)有所增加,但麻疹有所下降(从577.9降至499.2 mIU/ml,p<0.001)。2024年学龄前儿童(2 - 5岁)的免疫水平最高。
2019 - 2024年,人群对风疹、腮腺炎和水痘的免疫力提高,发病率降低,而麻疹免疫力下降,显示出存在薄弱环节。考虑到政策、公共卫生措施和人口统计学的相互作用,需要采取针对性策略(如针对青少年/成人的补种活动、优化婴儿疫苗接种)来加强保护。